Advances in the management of chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 7, 2003, Pages 1063-1082

  Ziedalski, Tomasz M ^a   Sankaranarayanan, Viji ^a   Chitkara, Rajinder K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Bronchodilators; Chronic obstructive pulmonary disease; Corticosteroids; Cytokines; Emphysema; Lekotrienes; Mucous; Phosphodiesterase; Prostanoids; Protease; Retinoids; Smoking; Therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIOXIDANT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; MATRIX METALLOPROTEINASE INHIBITOR; ORCIPRENALINE; OXITROPIUM BROMIDE; PIRBUTEROL ACETATE; PLACEBO; PROTEINASE INHIBITOR; RETINOID; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM; TIOTROPIUM BROMIDE; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XONPENEX;

CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST OF ILLNESS; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; LUNG ALVEOLUS; MYOPATHY; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; RASH; REVIEW; RISK FACTOR; SINUS TACHYCARDIA; SMOKING; SMOKING CESSATION;

EID: 0038445904     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.7.1063     Document Type: Review

References (213)

1. PAUWELS RA, BUIST AS, CALVERLEY PM et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. (2001) 163(5):1256-1276.
2. 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Respir. Crit. Care Med. (1996) 153(5):1530-1535.
3. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax (1997) 52(Suppl. 5)S1-S28.
4. Centers for Disease Control and Prevention. Current estimates from the National Health Interview Survey, 1995. Vital and health statistics. (1996)
5. MURRAY CJ, LOPEZ AD: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 (1996).
6. LOPEZ AD, MURRAY CC: The global burden of disease, 1990-2020. Nat. Med. (1998) 4(11):1241-1243.
7. National Center for Health Statistics. Report of final mortality statistics, 1979-1997 (1997).
8. EVANS MD, PRYOR WA. Cigarette smoking, emphysema, and damage to alpha 1-proteinase inhibitor. Am. J. Physiol. (1994) 266(6 Pt 1):L593-L611.
9. DAYAL H, KHUDER S, SHARRAR R et al.: Passive smoking in obstructive respiratory disease in an industrialized urban population. Environ. Res. (1994) 65(2):161-171.
10. LEUENBERGER P, SCHWARTZ J, ACKERMANN-LIEBRICH U et al.: Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am. J. Respir. Crit. Care Med. (1994) 150(5 Pt 1):1222-1228.
11. DENNIS RJ, MALDONADO D, NORMAN S et al.: Woodsmoke exposure and risk for obstructive airways disease among women. Chest (1996) 109(1):115-119.
12. HENDRICK DJ: Occupational and chronic obstructive pulmonary disease (COPD). Thorax (1996) 51(9):947-955.
13. 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax (1998) 53(6):501-505.
14. HUANG SL, SU CH, CHANG SC: Tumor necrosis factor-α gene polymorphism in chronic bronchitis. Am. J. Respir. Crit. Care Med. (1997) 156(5):1436-1439.
15. SMITH CA, HARRISON DJ: Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet (1997) 350(9078):630-633.
16. FINKELSTEIN R, FRASER RS, GHEZZO H et al.: Alveolar inflammation and its relation to emphysema in smokers. Am. J. Respir. Crit. Care Med. (1995) 152(5 Pt 1):1666-1672.
17. 1. Am. J. Respir. Crit. Care Med. (1997) 155(3):852-857.
18. PESCI A, BALBI B, MAJORI M et al.: Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur. Respir. J. (1998) 12(2):380-386.
19. KEATINGS VM, COLLINS PD, SCOTT DM et al.: Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. (1996) 153(2):530-534.
20. DI STEFANO A, CAPELLI A, LUSUARDI M et al.: Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. J. Respir. Crit. Care Med. (1998) 158(4):1277-1285.
21. MAJORI M, CORRADI M, CAMINATI A et al.: Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. (1999) 103(3 Pt 1):458-462.
22. HILL AT, BAYLEY D, STOCKLEY RA: The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. (1999) 160(3):893-898.
23. REPINE JE, BAST A, LANKHORST I: Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am. J. Respir. Crit. Care Med. (1997) 156(2 Pt 1):341-357.
24. PRATICO D, BASILI S, VIERI M et al.: Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2α-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. (1998) 158(6):1709-1714.
25. DEKHUIJZEN PN, ABEN K, DEKKER I et al.: Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1996) 154(3 Pt 1):813-816.
26. BARNES PJ, KARIN M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. (1997) 336(15):1066-1071.
27. STOCKLEY RA: Neutrophils and protease/antiprotease imbalance. Am. J. Respir. Crit. Care Med. (1999) 160(5 Pt 2):S49-S52.
28. GOTTLIEB DJ, STONE PJ, SPARROW D et al.: Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am. J. Respir. Crit. Care Med. (1996) 154(5):1290-1295.
29. REID PT, MARSDEN ME, CUNNINGHAM GA et al.: Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in Type II alveolar epithelial cells. FEBS Lett. (1999) 457(1):33-37.
30. CULPITT SV, MAZIAK W, LOUKIDIS S et al.: Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1999) 160(5 Pt 1):1635-1639.
31. FINLAY GA, O'DRISCOLL LR, RUSSELL KJ et al.: Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Respir. Crit. Care Med. (1997) 156(1):240-247.
32. OHNISHI K, TAKAGI M, KUROKAWA Y et al.: Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. (1998) 78(9):1077-1087.
33. HAUTAMAKI RD, KOBAYASHI DK, SENIOR RM et al.: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science (1997) 277(5334):2002-2004.
34. O'DONNELL DE, REVILL SM, WEBB KA: Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 164(5):770-777.
35. O'DONNELL DE, LAM M, WEBB KA: Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1998) 158(5 Pt 1):1557-1565.
36. HAY JG, STONE P, CARTER J et al.: Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur. Respir. J. (1992) 5(6):659-664.
37. VATHENEN AS, BRITTON JR, EBDEN P et al.: High-dose inhaled albuterol in severe chronic airflow limitation. Am. Rev. Resp. Dis. (1988) 138(4):850-855.
38. HIGGINS BG, POWELL RM, COOPER S et al.: Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur. Respir. J. (1991) 4(4):415-420.
39. CHRYSTYN H, MULLEY BA, PEAKE MD: Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ (1988) 297(6662):1506-1510.
40. WRIGHT J, BROCKLEBANK D, RAM F: Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD). Qual. Saf. Health Care (2002) 11(4):376-382.
41. BARNES PJ: Muscarinic receptor subtypes in airways. Eur. Respir. J. (1993) 6(3):328-331.
42. BEEH KM, WELTE T, BUHL R: Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration (2002) 69(4):372-379.
43. LIESKER J, WIJKSTRA PJ, TEN HACKEN NH et al.: A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest (2002) 121(2):597-608.
44. MARTIN RJ, BARTELSON BL, SMITH P et al.: Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest (1999) 115(5):1338-1345.
45. BARNES PJ: The pharmacological properties of tiotropium. Chest (2000) 117(Suppl. 2):63S-66S.
46. LITTNER MR, ILOWITE JS, TASHKIN DP et al.: Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2000) 161(4 Pt 1):1136-1142.
47. VAN NOORD JA, BANTJE TA, ELAND ME et al.: A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax (2000) 55(4):289-294.
48. CASABURI R, BRIGGS D Jr, DONOHUE JF et al.: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest (2000) 118(5):1294-1302.
49. VINCKEN W, VAN NOORD JA, GREEFHORST AP et al.: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. (2002) 19(2):209-216.
50. CASABURI R, MAHLER DA, JONES PW et al.: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. (2002) 19(2):217-224.
51. DONOHUE JF, VAN NOORD JA, BATEMAN ED et al.: A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest (2002) 122(1):47-55.
52. 2-agonists in asthma treatment. Pauwels R, O'Byrne PM (Eds), Barnes & Noble, USA (1997):35-36.
53. 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2002) 4:CD001495.
54. SHIM CS, WILLIAMS MH, JR.: Bronchodilator response to oral aminophylline and terbutaline versus aerosol albuterol in patients with chronic obstructive pulmonary disease. Am. J. Med. (1983) 75(4):697-701.
55. ULRIK CS: Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax (1995) 50(7):750-754.
56. BOYD G, MORICE AH, POUNSFORD JC et al.: An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. (1997) 10(4):815-821.
57. 2-agonists. Respir. Med. (2001) 95(Suppl. B )S7-S11.
58. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 163(5):1087-1092.
59. MAHLER DA, DONOHUE JF, BARBEE RA et al.: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest (1999) 115(4):957-965.
60. 2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst. Rev. (2002) 3:CD001104.
61. AYERS ML, MEJIA R, WARD J et al.: Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur. Respir. J. (2001) 17(6):1132-1137.
62. PATAKAS D, ANDREADIS D, MAVROFRIDIS E et al.: Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir. Med. (1998) 92(9):1116-1121.
63. WEINER P, MAGADLE R, BERAR-YANAY N et al.: The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. Chest (2000) 118(3):672-678.
64. 2-adrenergic agonists in COPD. Chest (2001) 120(1 ):258-270.
65. BENHAMOU D, CUVELIER A. MUIR JF et al.: Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir. Med. (2001) 95(10):817-821.
66. AALBERS R, AYRES J, BACKER V et al.: Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur. Respir. J. (2002) 19(5):936-943.
67. CAZZOLA M, CENTANNI S, REGORDA C et al.: Onset of action of single doses of formoterol administered via turbuhaler in patients with stable COPD. Pulm. Pharmacol. Ther. (2001) 14(1):41-45.
68. CAZZOLA M, D'AMATO M, CALIFANO C et al.: Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin. Ther. (2002) 24(4):595-604.
69. DAHL R, GREEFHORST LA, NOWAK D et al.: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 164(5):778-784.
70. HOGAN TJ, GEDDES R, GONZALEZ ER: An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin. Ther. (2003) 25(1):285-297.
71. WADBO M, LOFDAHL CG, LARSSON K et al.: Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-oontrolled study. Eur. Respir. J. (2002) 20(5):1138-1146.
72. LIESKER J, VAN DE VELDE V, MEYSMAN M et al.: Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir. Med. (2002) 96(8):559-566.
73. ROSSI A, KRISTUFEK P, LEVINE BE et al.: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest (2002) 121(4):1058-1069.
74. KOTTAKIS J, CIOPPA GD, CREEMERS J et al.: Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can. Respir. J. (2002) 9(2):107-115.
75. CELIK G, KAYACAN O, BEDER S et al.: Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration (1999) 66(5):434-439.
76. CAZZOLA M, SANTANGELO G, PICCOLO A et al.: Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. (1994) 7(2):103-107.
77. CAZZOLA M, MATERA MG, SANTANGELO G et al.: Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir. Med. (1995) 89(5):357-362.
78. CAZZOLA M, DI PERNA F, NOSCHESE P et al.: Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur. Respir. J. (1998) 11(6):1337-1341.
79. AU DH, CURTIS JR, EVERY NR et al.: Association between inhaled β-agonists and the risk of unstable angina and myocardial infarction. Chest (2002) 121(3):846-851.
80. 2-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease. Eur. J. Clin. Pharmacol. (1996) 49(5):341-345.
81. EIDELMAN DH, SAMI MH, MCGREGOR M et al.: Combination of theophylline and salbutamol for arrhythmias in severe COPD. Chest (1987) 91(6):808-812.
82. ROSSINEN J, PARTANEN J, STENIUS-AARNIALA B et al.: Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease. J. Intern. Med. (1998) 243(5):361-366.
83. SUISSA S, ASSIMES T, ERNST P: Inhaled short-acting β agonist use in COPD and the risk of acute myocardial infarction. Thorax (2003) 58(1):43-46.
84. SEIDER N, ABINADER EG, OLIVEN A: Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease. Chest (1993) 104(4):1070-1074.
85. CAZZOLA M, IMPERATORE F, SALZILLO A et al.: Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest (1998) 114(2):411-415.
86. HOGG JC, MACKLEM PT, THURLBECK WM: Site and nature of airway obstruction in chronic obstructive lung disease. N. Engl. J. Med. (1968) 278(25):1355-1360.
87. SIAFAKAS NM, VERMEIRE P, PRIDE NB et al.: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur. Respir. J. (1995) 8(8):1398-1420.
88. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am. J. Respir. Crit. Care Med. (1995) 152(5 Pt 2):S77-S121.
89. CALLAHAN CM, DITTUS RS, KATZ BP: Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann. Intern. Med. (1991) 114(3):216-223.
90. WEIR DC, GOVE RI, ROBERTSON AS et al.: Response to corticosteroids in chronic airflow obstruction: relationship to emphysema and airways collapse. Eur. Respir. J. (1991) 4(10):1185-1190.
91. SENDEROVITZ T, VESTBO J, FRANDSEN J et al.: Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir. Med. (1999) 93(10):715-718.
92. POSTMA DS, PETERS I, STEENHUIS EJ et al.: Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur. Respir. J. (1988) 1(1):22-26.
93. POSTMA DS, STEENHUIS EJ, VAN DER WEELE LT et al.: Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur. J. Respir. Dis. (1985) 67(1):56-64.
94. DECRAMER M, STAS KJ: Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am. Rev. Respir. Dis. (1992) 146(3):800-802.
95. DECRAMER M, LACQUET LM, FAGARD R et al.: Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am. J. Respir. Crit. Care Med. (1994) 150(1):11-16.
96. DECRAMER M, DE BOCK V, DOM R: Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1996) 153(6 Pt 1):1958-1964.
97. WOOD-BAKER R, WALTERS E: Corticosteroids for treating acute exacerbation of chronic obstructive pulmonary disease. Cochrane Library (1998) 4th edn. (Oxford: update software, 1998).
98. ALBERT RK, MARTIN TR, LEWIS SW: Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann. Intern. Med. (1980) 92(6):753-758.
99. DAVIES L, ANGUS RM, CALVERLEY PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet (1999) 354(9177):456-460.
100. EMERMAN CL, CONNORS AF, LUKENS TW et al.: A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest (1989) 95(3):563-567.
101. THOMPSON WH, NIELSON CP, CARVALHO P et al.: Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am. J. Respir. Crit. Care Med. (1996) 154(2 Pt 1):407-412.
102. NIEWOEHNER DE, ERBLAND ML, DEUPREE RH et al.: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N. Engl. J. Med. (1999) 340(25):1941-1947.
103. SINGH JM, PALDA VA, STANBROOK MB et al.: Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch. Intern. Med. (2002) 162(22):2527-2536.
104. SHORTALL SP, BLUM J, OLDENBURG FA et al.: Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regimen and an intravenous/nebulizer regimen. Respir. Care (2002) 47(2):154-158.
105. NISHIMURA K, KOYAMA H, IKEDA A et al.: The effect of high-dose inhaled beclomethasone dipropionate in patients with stable COPD. Chest (1999) 115(1):31-37.
106. PAGGIARO PL, DAHLE R, BAKRAN I et al.: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet (1998) 351(9105):773-780.
107. VAN GRUNSVEN PM, VAN SCHAYCK CP, DERENNE JP et al.: Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax (1999) 54(1):7-14.
108. BURGE PS, CALVERLEY PM, JONES PW et al.: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ (2000) 320(7245):1297-1303.
109. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. Lung Health Study Research Group. N. Engl. J. Med. (2000) 343(26):1902-1909.
110. VESTBO J, SORENSEN T, LANGE P et al.: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (1999) 353(9167):1819-1823.
111. PAUWELS RA, LOFDAHL CG, LAITINEN LA et al.: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. (1999) 340(25):1948-1953.
112. ALSAEEDI A, SIN D, MCALISTER FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. (2002) 113(1):59-65.
113. JONES PW WILLITS LR, BURGE PS et al.: Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respir. J. (2003) 21(1):68-73.
114. SIN DD, TU JV: Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 164(4):580-584.
115. JARAD NA, WEDZICHA JA, BURGE PS et al.: An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir. Med. (1999) 93(3):161-166.
116. VAN DER VALK P, MONNINKHOF E, VAN DER PALEN J et al.: Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. (2002) 166(10):1358-1363.
117. JOHNELL O, PAUWELS R, LOFDAHL CG et al.: Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur. Respir. J. (2002) 19(6):1058-1063.
118. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest (1994) 105(5):1411-1419.
119. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest (1997) 112(6):1514-1521.
120. CHRISCHILLES E, GILDEN D, KUBISIAK J et al.: Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am. J. Manag. Care (2002) 8(10):902-911.
121. VAN NOORD JA, DE MUNCK DR, BANTJE TA et al.: Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. J. (2000) 15(5):878-885.
122. ZUWALLACK RL, MAHLER DA, REILLY D et al.: Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest (2001) 119(6):1661-1670.
123. CAZZOLA M, DI LORENZO G, DI PERNA F et al.: Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest (2000) 118(6):1576-1581.
124. BARNES PJ: Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur. Respir. J. (2002) 19(1):182-191.
125. MAK JC, NISHIKAWA M, SHIRASAKI H et al.: Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J. Clin. Invest. (1995) 96(1):99-106.
126. ADCOCK IM, MANEECHOTESUWAN K, USMANI O: Molecular interactions between glucocorticoids and long-acting beta2-agonists. J. Allergy Clin. Immunol. (2002) 110(6 Suppl.):S261-S268.
127. MAHLER DA, WIRE P, HORSTMAN D et al.: Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. (2002) 166(8):1084-1091.
128. SZAFRANSKI W, CUKIER A, RAMIREZ A et al.: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. (2003) 21(1):74-81.
129. CALVERLEY P, PAUWELS R, VESTBO J et al.: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 361(9356):449-456.
130. TORPHY TJ: Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. (1998) 157(2):351-370.
131. VASSALLO R, LIPSKY JJ: Theophylline: recent advances in the undemanding of its mode of action and uses in clinical practice. Mayo Clin. Proc. (1998) 73(4):346-354.
132. BARNES PJ: Chronic obstructive pulmonary disease. N. Engl. J. Med. (2000) 343(4):269-280.
133. FERGUSON GT: Update on pharmacologic therapy for chronic obstructive pulmonary disease. Clin. Chest Med. (2000) 21(4):723-738.
134. CHITKARA RK, SARINAS PS: Recent advances in diagnosis and management of chronic bronchitis and emphysema. Curr. Opin. Pulm. Med. (2002) 8(2):126-136.
135. RAM FS, JONES PW, CASTRO AA et al.: Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2002) 4:CD003902.
136. GAUTHIER AP, YAN S, SLIWINSKI P et al.: Effects of fatigue, fiber length, and aminophylline on human diaphragm contractility. Am. J. Respir. Crit. Care Med. (1995) 152(1):204-210.
137. VAZ FRAGOSO CA, MILLER MA: Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. (1993) 147(6 Pt 2):S40-S47.
138. Tobacco use-United States, 1900-1999. MMWR Morb. Mortal. Wkly Rep. (1999) 48(43):986-993.
139. RIGOTTI NA: Clinical practice. Treatment of tobacco use and dependence. N. Engl. J. Med. (2002) 346(7):506-512.
140. The health benefits of smoking cessation: a report of the Surgeon General (1990) (DHHS publication no. (CDC) 90-8416).
141. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA (2000) 283(24):3244-3254.
142. HUGHES JR, GOLDSTEIN MG, HURT RD et al.: Recent advances in the pharmacotherapy of smoking. JAMA (1999) 281(1):72-76.
143. LANCASTER T, STEAD L, SILAGY C et al.: Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ (2000) 321(7257):355-358.
144. HAJEK P, WEST R, FOULDS J et al.: Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch. Intern. Med. (1999) 159(17):2033-2038.
145. BOHADANA A, NILSSON F, RASMUSSEN T et al.: Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch. Intern. Med. (2000) 160(20):3128-3134.
146. Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. Arch. Intern. Med. (1994) 154(9):989-995.
147. JOSEPH AM, NORMAN SM, FERRY LH et al.: The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N. Engl. J. Med. (1996) 335(24):1792-1798.
148. BENOWITZ NL, GOURLAY SG: Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J. Am. Coll. Cardiol. (1997) 29(7):1422-1431.
149. SACHS DP, BENOWITZ NL: Individualizing medical treatment for tobacco dependence. Eur. Respir. J. (1996) 9(4):629-631.
150. LILLINGTON GA, LEONARD CT, SACHS DP: Smoking cessation. Techniques and benefits. Clin. Chest Med. (2000) 21(1):199-208, xi.
151. JORENBY DE, LEISCHOW SJ, NIDES MA et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. (1999) 340(9):685-691.
152. HALL SM, REUS VI, MUNOZ RF et al.: Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry (1998) 55(8):683-690.
153. PROCHAZKA AV, WEAVER MJ, KELLER RT et al.: A randomized trial of nortriptyline for smoking cessation. Arch. Intern. Med. (1998) 158(18):2035-2039.
154. ROSE JE, BEHM FM, WESTMAN EC et al.: Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. (1994) 56(1):86-99.
155. ROSE JE, BEHM FM, WESTMAN EC: Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacol. Biochem. Behav. (2001) 68(2):187-197.
156. BRAUER LH, BEHM FM, WESTMAN EC et al.: Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology (Berl) (1999) 143(4):339-346.
157. ROSE JE, WESTMAN EC, BEHM FM et al.: Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacol. Biochem. Behav. (1999) 62(1):165-172.
158. WATKINS S, EPPING-JORDAN MP, KOOB GF et al.: Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol. Biochem. Behav. (1999) 62(4):743-751.
159. DRAZEN JM: Leukotrienes as mediators of airway obstruction. Am. J. Respir. Crit. Care Med. (1998) 158(5 Pt 3):S193-S200.
160. DRAZEN JM, ISRAEL E, O'BYRNE PM: Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. (1999) 340(3):197-206.
161. COLEMAN RA, EGLEN RM, JONES RL et al.: Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv. Prostaglandin Thromboxane Leukot. Res. (1995) 23:283-285.
162. YOKOMIZO T, IZUMI T, CHANG K et al.: A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature (1997) 387(6633):620-624.
163. CAZZOLA M, CENTANNI S, BOVERI B et al.: Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. Respiration (2001) 68(5):452-459.
164. GOMPERTZ S, STOCKLEY RA: A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest (2002) 122(1):289-294.
165. LEE E, LINDO T, JACKSON N et al.: Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am. J. Respir. Crit. Care Med. (1999) 160(6):2079-2085.
166. KILFEATHER S: 5-lipoxygenase inhibitors for the treatment of COPD. Chest (2002) 121(5 Suppl.):197S-200S.
167. VERNOOY JH, KUCUKAYCAN M, JACOBS JA et al.: Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am. J. Respir. Crit. Care Med. (2002) 166(9):1218-1224.
168. DE BOER WI, SONT JK, VAN SCHADEWIJK A et al.: Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J. Pathol. (2000) 190(5):619-626.
169. WHITE JR, LEE JM, YOUNG PR et al.: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. (1998) 273(17):10095-10098.
170. YANG XD, CORVALAN JR, WANG P et al.: Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol. (1999) 66(3):401-410.
171. DE BOER WI: Cytokines and therapy in COPD: a promising combination? Chest (2002) 121(5 Suppl.):209S-218S.
172. JONES SA, DEWALD B, CLARK-LEWIS I et al.: Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. J. Biol. Chem. (1997) 272(26):16166-16169.
173. PRETOLANI M: Interleukin-10: an anti-inflammatory cytokine with therapeutic potential. Clin. Exp. Allergy (1999) 29(9):1164-1171.
174. TAKANASHI S, HASEGAWA Y, KANEHIRA Y et al.: Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur. Respir. J. (1999) 14(2):309-314.
175. MASCALI J, CVIETUSA P, NEGRI J et al.: Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann. Allergy Asthma Immunol. (1996) 77(1):34-38.
176. PITSIOU G, KYRIAZIS G, HATZIZISI O et al.: Tumor necrosis factor-alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir. Med. (2002) 96(8):594-598.
177. WOUTERS EF, CREUTZBERG EC, SCHOLS AM: Systemic effects in COPD. Chest (2002) 121(5 Suppl.):127S-130S.
178. SCHMITZ H, FROMM M, BENTZEL CJ et al.: Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J. Cell Sci. (1999) 112(Pt 1):137-146.
179. KAMPF C, RELOVA AJ, SANDLER S et al.: Effects of TNF-alpha, IFN-gamma and IL-beta on normal human bronchial epithelial cells. Eur. Respir. J. (1999) 14(1):84-91.
180. SULKOWSKA M, SULKOWSKI S, TERLIKOWSKI S et al.: Tumor necrosis factor-alpha induces emphysema-like pulmonary tissue rebuilding. Changes in Type II alveolar epithelial cells. Pol. J. Pathol. (1997) 48(3):179-188.
181. VAN DEN BOSCH F, KRUITHOF E, DE VOS M et al.: Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet (2000) 356(9244):1821-1822.
182. KLIPPEL JH: Biologic therapy for rheumatoid arthritis. N. Engl. J. Med. (2000) 343(22):1640-1641.
183. BELL S, KAMM MA: Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. Lancet (2000) 355(9207):858-860.
184. FELDMAN M, TAYLOR P, PALEOLOG E et al.: Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant. Proc. (1998) 30(8):4126-4127.
185. PELA R, CALCAGNI AM, SUBIACO S et al.: N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration (1999) 66(6):495-500.
186. KAWIKOVA I, BARNES PJ, TAKAHASHI T et al.: 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. Am. J. Respir. Crit. Care Med. (1996) 153(2):590-596.
187. HORIGUCHI T, TACHIKAWA S, KONDO R et al.: Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema. Arzneimittelforschung (2002) 52(10):764-768.
188. ENDO S, AKIYAMA K: [Thromboxane A2 receptor antagonist in asthma therapy]. Nippon Rinsho (1996) 54(11):3045-3048.
189. 1-antitrypsin deficiency, Pi Z. Acta Med. Scand. (1978) 204(5):345-351.
190. 1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur. Respir. J. (1997) 10(10):2260-2263.
191. SALLENAVE JM, SHULMANN J, CROSSLEY J et al.: Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell Mol. Biol. (1994) 11(6):733-741.
192. MCELVANEY NG, DOUJAIJI B, MOAN MJ et al.: Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am. Rev. Respir. Dis. (1993) 148(4 Pt 1):1056-1060.
193. WILLIAMS JC, FALCONE RC, KNEE C et al.: Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am. Rev. Respir. Dis. (1991) 144(4):875-883.
194. OHBAYASHI H: Neutrophil elastase inhibitors as treatment for COPD. Expert Opin. Investig. Drugs (2002) 11(7):965-980.
195. LUISETTI M, STURANI C, SELLA D et al.: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur. Respir. J. (1996) 9(7):1482-1486.
196. Marimastat: BB 2516, TA 2516. Drugs R D (2003) 4(3):198-203.
197. TEIXEIRA M, GRISTWOOD RW, COOPER N et al.: Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. (1997) 18(5):164-171.
198. STURTON G, FITZGERALD M: Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest (2002) 121(5 Suppl.):192S-196S.
199. COMPTON CH, GUBB J, NIEMAN R et al.: Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet (2001) 358(9278):265-270.
200. NELL H, LEICHTL S, RATHGEB M: Acute anti-inflammatory effect of the novel phosphodiesterase inhibitor roflumilast on allergen challenge in asthmatics after a single dose [abstract]. Am. J. Respir. Crit. Care Med. (2000) 161(suppl.):A200.
201. KELLERMAN DJ: P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance. Chest (2002) 121(5 Suppl.):201S-205S.
202. BENNETT WD, ZEMAN KL, FOY C et al.: Effect of aerosolized uridine 5′-triphosphate on mucociliary clearance in mild chronic bronchitis. Am. J. Respir. Crit. Care Med. (2001) 164(2):302-306.
203. NOONE PG, BENNETT WD, REGNIS JA et al.: Effect of aerosolized uridine-5′-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia. Am. J. Respir. Crit. Care Med. (1999) 160(1):144-149.
204. BENNETT WD, OLIVIER KN, ZEMAN KL et al.: Effect of uridine 5′-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am. J. Respir. Crit. Care Med. (1996) 153(6 Pt 1 ):1796-1801.
205. KELLERMAN DJ, BENNETT WD, ZEMAN KL: Dose response relationship of the P2Y2 agonist INS365 of mucociliary clearance in smokers. J. Allergy Clin. Immunol. (2001) 107:S164 [abstract].
206. JOOS GF, DE SWERT KO, PAUWELS RA: Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Eur. J. Pharmacol. (2001) 429(1-3):239-250.
207. RAMNARINE SI, HIRAYAMA Y, BARNES PJ et al.: 'Sensory-efferent' neural control of mucus secretion: characterization using tachykinin receptor antagonists in ferret trachea in vitro. Br. J. Pharmacol. (1994) 113(4):1183-1190.
208. VAN SCHOOR J, JOOS GF, CHASSON BL et al.: The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur. Respir. J. (1998) 12(1):17-23.
209. JOOS G, VINCKEN W, LOUIS RE et al.: The effect of the dual NK1/NK2 tachykinin receptor antagonist DNK333A on neurokinin A-induced bronchoconstriction in patients with asthma. Am. J. Respir. Crit. Care Med. (2001) 163(A628.
210. ROGERS DF: Tachykinin receptor antagonists for asthma and COPD. Expert Opin. Ther. Patents (2001) 11(7):1097-1121.
211. MCGOWAN SE: Contributions of retinoids to the generation and repair of the pulmonary alveolus. Chest (2002) 121(5 Suppl.):206S-208S.
212. MASSARO GD, MASSARO D: Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med. (1997) 3(6):675-677.
213. MAO JT, GOLDIN JG, DERMAND J et al.: A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am. J. Respir. Crit. Care Med. (2002) 165(5):718-723.